



### Demographics and socioeconomic

Total Population (in 1000) (2020)	71.75
Population <1 year of age (in 1000) (2020)	0.80
Population 1 year of age (in 1000) (2020)	0.80
Population <5 years of age (in 1000) (2020)	4.01
Women of childbearing age (in 1000) (2020)	40.94
Infant Mortality Rate (per 1000 live births) (2018)	1.9
Gross national income (US\$ per capita) current value (2019)	117,740.0
National Health Expenditure Public (2018)	0.0
National Health Expenditure Private (2018)	0.0

### Immunization system highlights

- There is no comprehensive multi-year plan (MYP) for immunization.
- There is no information available on the national technical advisory group on immunization.
- No information is available on spending on routine immunization financed using government funds.
- No information is available on spending on vaccine purchase financed using government funds.
- A national nominal electronic immunization registry implementation is in progress.


### Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	1989
Hepatitis B	1998
HPV	2007
Influenza	
MMR1	1979
MMR2	
Pentavalent	
Pneumococcal Conjugate	2003
Rotavirus	2016
Tdap	2007
Tetavalent DPT-Hib or DPT-HepB	
Yellow Fever	

### Immunization Schedule

BMU	Doses					
	1	2	3	4	5	6
BCG	NA					
HepB pediatric	M6	M7	M12			
DTP-Hib						
DTP-Hib-HepB						
DTP-Hib-IPV	M2	M4	M6	M18		
DTP-Hib-HepB-IPV						
DTP						
Influenza pediatric	M6-Y18					
IPV	1st contact					
OPV						
MMR	M15	Y4-Y6				
Pneumoco conjugate	M2	M4	M6	M18		
Rotavirus	M2	M4				
Td						
Tdap						Y11-18
HPV	Y11	+M6-M12				

### Vaccination Coverage



### Surveillance indicators

#### Acute flaccid paralysis (AFP) - (CARPHA) 2020


Number of AFP suspected cases	4
AFP rate per 100,000 population <15 years old	0.22
% of cases with 1 adequate samples	25
% of cases investigated within <48 hours	50
% sites reporting	72

#### Measles-rubella (MR) - (CARPHA) 2020


Number of MR suspected cases	55
% of cases with adequate investigation	60
% of cases with adequate blood samples	96
% of samples received in laboratory <=5 days	22
% of laboratory samples results <=4 days	76




### Polio3 coverage and AFP rate per 100,000 children <15 years of age




### DTP3 coverage and number of reported diphtheria and pertussis cases




### Number of tetanus (no neonatal) and neonatal tetanus cases



### Proportion of municipalities by coverage range with DTP3 in children <1 years of age



### DTP1-DTP3 and DTP1-MMR1 Dropout Rate



**Legend**  
 NB/nb-newborn  
 M/m -month  
 Y/y-year  
 WCBA-women of childbearing age  
 ● with stockout  
 ● no stockout  
 ○ no data available  
 NA - not applicable

### Vaccine Stockout

BMU	2013	2014	2015	2016	2017	2018	2019	2020
AD syringes								
BCG		●	●	●	●	●	●	●
Disposable syringes			●	●	●	●	●	●
DTP	●	●	●	●	●	●	●	●
HepB		●	●	●	●	●	●	●
Hib	●	●	●	●	●	●	●	●
Influenza		●	●	●	●	●	●	●
IPV		●	●	●	●	●	●	●
Measles		●	●	●	●	●	●	●
Pneumo. conjugate		●	●	●	●	●	●	●
Polio								
Reconst. syringes				●	●	●	●	●
Rotavirus				●	●	●	●	●
Safety boxes		●	●	●	●	●	●	●
Tdap		●	●	●	●	●	●	●
TT	●	●	●	●	●	●	●	●
Yellow fever		●	●	●	●	●	●	●